Erschienen in:
04.01.2022 | COVID-19 | Original Paper
Zur Zeit gratis
COVID-19: vaccination vs. hospitalization
verfasst von:
Oguz Uzun, Tekin Akpolat, Ayhan Varol, Sema Turan, Serife Gokbulut Bektas, Pelin Duru Cetinkaya, Mazlum Dursun, Nurten Bakan, Burcu Baran Ketencioglu, Murat Bayrak, Serap Argun Baris, Rahmet Guner, Ozgur Gunal, Serkan Nural, Pelin Pinar Deniz, Oya Baydar Toprak, Gulcihan Ozkan, Ayça Gumus, Ferhan Kerget, Merve Ercelik, Ozlem Ataoglu, Aycan Yuksel, Gungor Ates, Oya Eren Kutsoylu, Neslihan Kose, Deniz Kizilirmak, Serdar Keskin, Okkes Gultekin, Nilüfer Coskun, Emine Serap Yilmaz, Selen Uslu, İlknur Basyigit, Begüm Ergan, Figen Deveci, Mehmet Nuri Yakar, Cigdem Zuhur, Gulseren Sagcan, Zeynep Ture Yuce, Mutlu Kuluozturk, Mehmet Emin Sezgin, Esma Nur Aktepe Sezgin, Yavuz Havlucu, Caglar Cuhadaroglu, Oguz Kilinc, Hasim Boyaci, Hayriye Altunay, Mehmet Akti, Zehra Bastepe Dursun, Ayse Kaya Kalem, Sinem Akkaya Isik, Levent Akyildiz, Nilüfer Aykac, Mehmet Selim Almaz, Nurdan Kokturk, Oya Itil
Erschienen in:
Infection
|
Ausgabe 3/2022
Einloggen, um Zugang zu erhalten
Abstract
Objective
Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols.
Setting
Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose.
Methods
We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status.
Results
We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac.
Conclusion
Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination.